

# Leonid D Zamora

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4411179/publications.pdf>

Version: 2024-02-01

19  
papers

436  
citations

933264

10  
h-index

940416

16  
g-index

19  
all docs

19  
docs citations

19  
times ranked

443  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. <i>Arthritis Research and Therapy</i> , 2017, 19, 62.	1.6	100
2	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. <i>Lancet Rheumatology</i> , The, 2019, 1, e95-e102.	2.2	65
3	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e24-e30.	2.2	45
4	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. <i>Arthritis Research and Therapy</i> , 2016, 18, 260.	1.6	44
5	Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. <i>Lancet Rheumatology</i> , The, 2019, 1, e103-e110.	2.2	38
6	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. <i>Lancet Rheumatology</i> , The, 2021, 3, e517-e531.	2.2	26
7	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 425-433.	0.9	24
8	“Not at target”™: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, 70.	1.6	17
9	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , The, 2022, 4, e441-e449.	2.2	17
10	Risk factors for herpes zoster infection among Filipinos with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 197-202.	0.9	12
11	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1255-1257.	0.9	12
12	Biologic therapies in systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 146-153.	0.9	11
13	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , 2021, 60, 5185-5193.	0.9	9
14	Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 2033-2041.	1.5	6
15	Serotonin syndrome masquerading as disease flare in lupus nephritis with end-stage renal disease. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1933-1936.	0.9	5
16	Lupus education for physicians and patients in a resource-limited setting. <i>Clinical Rheumatology</i> , 2020, 39, 697-702.	1.0	5
17	OP0246...ATTAINMENT OF THE LUPUS LOW DISEASE ACTIVITY STATE IS ASSOCIATED WITH PROTECTION FROM DAMAGE ACCRUAL IN PATIENTS WITH ACTIVE DISEASE AT BASELINE. , 2019, , .		0
18	OP0330...#X00A0; COMPARISON OF THE EFFECTS OF DORIS REMISSION AND LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) ON DISEASE OUTCOMES IN A MULTINATIONAL PROSPECTIVE STUDY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	THU0253â€¦EFFECT OF GLUCOCORTICIDS ON DAMAGE ACCRUAL IN SLE PATIENTS WITH NO CLINICAL OR SEROLOGICAL DISEASE ACTIVITY. , 2019, , .		0